Clinical Microbiology Newsletter
Volume 32, Issue 10 , Pages 77-78 , 15 May 2010

Carbapenemase-Producing Serratia marcescens: the Treatment Conundrum

  • Jennifer Dien Bard, Ph.D.

      Affiliations

    • UCLA David Geffen School of Medicine, Department of Pathology and Laboratory Medicine, California
    • Corresponding Author InformationMailing Address: Jennifer Dien Bard, Ph.D., Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, 10833 LeConte Ave., Brentwood Annex, Mail Code 173216, Los Angeles, CA 90095-1732. Tel.: 310-794-2761. Fax: 310-794-2765
    • ,
  • Janet F. Hindler, M.S.

      Affiliations

    • UCLA Medical Center, Los Angeles, California
    • ,
  • Michael A. Lewinski, Ph.D.

      Affiliations

    • UCLA David Geffen School of Medicine, Department of Pathology and Laboratory Medicine, California
    • UCLA Medical Center, Los Angeles, California

References 

  1. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing. 19th informational supplement. Document M100-S19. CLSI, Wayne, PA.
  2. Livermore DM . Acquired carbapenemases . J. Antimicrob. Chemother . 1997;39:673–676
  3. Rasmussen BA , Bush K . Carbapenem-hydrolyzing beta-lactamases . Antimicrob. Agents Chemother . 1997;41:223–232
  4. Queenan AM , Bush K . Carbapenemases: the versatile beta-lactamases . Clin. Microbiol. Rev. . 2007;20:440–458
  5. Naas T , et al.   Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6 . Antimicrob. Agents Chemother . 1994;38:1262–1270
  6. Yigit H , et al.   Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae . Antimicrob. Agents Chemother . 2001;45:1151–1161
  7. Bradford PA , et al.   Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City . Clin. Infect. Dis. . 2004;39:55–60
  8. Castanheira M , et al.   Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program . Antimicrob. Agents Chemother . 2008;52:570–573
  9. Deshpande LM , et al.   Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999–2005) . Diagn. Microbiol. Infect. Dis. . 2006;56:367–372
  10. Queenan AM , et al.   SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains . Antimicrob. Agents Chemother . 2000;44:3035–3039
  11. Carrer A , et al.   Occurrence of an SME-2-producing Serratia marcescens isolate in Canada . Int. J. Antimicrob. Agents . 2008;31:181–182
  12. Poirel L , et al.   SME-2-producing Serratia marcescens isolate from Switzerland . Antimicrob. Agents Chemother . 2007;51:2282–2283
  13. Gales AC , et al.   Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f beta-lactamase (SME-1) in the United States: results from the MYSTIC Programme . Diagn. Microbiol. Infect. Dis. . 2001;39:125–127
  14. Majiduddin FK , Palzkill T . Amino acid residues that contribute to substrate specificity of class A beta-lactamase SME-1 . Antimicrob. Agents Chemother . 2005;49:3421–3427
  15. Queenan AM , et al.   SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases . Antimicrob. Agents Chemother . 2006;50:3485–3487

PII: S0196-4399(10)00020-6

doi: 10.1016/j.clinmicnews.2010.04.004

Clinical Microbiology Newsletter
Volume 32, Issue 10 , Pages 77-78 , 15 May 2010

Article Tools